Analysts Set Expectations for AVXL Q1 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Anavex Life Sciences in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.55) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04.

A number of other research analysts have also recently commented on AVXL. Jones Trading cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. D. Boral Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Price Performance

Anavex Life Sciences stock opened at $3.88 on Wednesday. The firm has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $6.95. The stock has a market cap of $359.56 million, a price-to-earnings ratio of -8.43 and a beta of 1.21. Anavex Life Sciences has a 1-year low of $2.86 and a 1-year high of $13.99.

Hedge Funds Weigh In On Anavex Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in Anavex Life Sciences by 2.8% in the second quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock valued at $18,624,000 after acquiring an additional 54,985 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Anavex Life Sciences by 6.5% in the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock valued at $9,229,000 after purchasing an additional 63,685 shares during the last quarter. Nwam LLC raised its holdings in shares of Anavex Life Sciences by 2.4% in the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock valued at $9,446,000 after purchasing an additional 24,128 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Anavex Life Sciences by 187.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company’s stock worth $3,108,000 after purchasing an additional 569,579 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Anavex Life Sciences by 55.8% in the second quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock valued at $7,966,000 after buying an additional 309,605 shares during the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

More Anavex Life Sciences News

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target (implying large upside) and published FY2027 and quarterly EPS forecasts that are less negative than consensus (FY2027 -$0.55 vs consensus -$0.69) — supportive for sentiment and valuation expectations. MarketBeat – AVXL HC Wainwright Report
• Positive Sentiment: Analysis pieces argue Anavex may be approaching cash‑flow breakeven, a narrative investors view positively for a small biotech with ongoing R&D spend. Breakeven On The Horizon For Anavex Life Sciences (Yahoo)
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript is available for investors wanting primary detail on recent results and management commentary; it may clarify near‑term guidance but contains no single market‑moving surprise. Q1 2026 Earnings Call Transcript (MSN)
• Neutral Sentiment: Short‑interest reports show 0 shares and a days‑to‑cover of 0.0, but entries include NaN and appear to be data glitches — there is no clear evidence of new short pressure driving the move. (No linked source; reported in market data feed.)
• Negative Sentiment: A Seeking Alpha piece highlights a negative European regulator opinion on blarcamesine, Anavex’s lead asset, calling the program into “regulatory purgatory” — that regulatory uncertainty is the most direct near‑term negative for valuation and explains downward pressure. Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (Seeking Alpha)

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.